公开(公告)号：US07563808B2

公开(公告)日：2009-07-21

申请号：US10732349

申请日：2003-12-11

申请人： Raymond Pratt

发明人： Raymond Pratt

IPC分类号： A61K31/445

CPC分类号： A61K31/445

摘要： The invention describes novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or dementia associated with neurologic and/or psychiatric conditions, including epilepsy, brain tumors, brain lesions, multiple sclerosis, Down's syndrome, Rett's syndrome, progressive supranuclear palsy, frontal lobe syndrome, and schizophrenia and related psychiatric disorders; cognitive impairments caused by traumatic brain injury, post coronary artery by-pass graft surgery, electroconvulsive shock therapy, and chemotherapy, administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The invention also describes novel methods for treating and preventing delirium, Tourette's syndrome, myasthenia gravis, attention deficit hyperactivity disorder, autism, dyslexia, mania, depression, apathy, and myopathy associated with diabetes by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The invention also describes novel methods for delaying the onset of Alzheimer's disease, for enhancing cognitive functions, for treating and preventing sleep apnea, for alleviating tobacco withdrawal syndrome, and for treating the dysfunctions of Huntington's Disease by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. A preferred cholinesterase inhibitor for use in the methods of the invention is donepezil hydrochloride or ARICEPT®.

摘要翻译： 本发明描述了用于治疗和预防由血管疾病引起的痴呆的新方法; 与帕金森病有关的痴呆; 路易体痴呆症 艾滋病痴呆; 轻度认知障碍; 年龄相关记忆障碍; 与神经和/或精神病学条件相关的认知障碍和/或痴呆，包括癫痫，脑肿瘤，脑损伤，多发性硬化，唐氏综合征，雷特综合征，进行性核上性麻痹，额叶综合征和精神分裂症及相关精神疾病; 由创伤性脑损伤，冠状动脉旁路移植手术，电惊醒性休克治疗和化疗引起的认知障碍，施用治疗有效量的至少一种本文所述的胆碱酯酶抑制剂化合物。 本发明还描述了通过施用治疗有效量的至少一种以上的治疗和预防呃妄，杜蕾特综合征，重症肌无力，注意缺陷多动障碍，自闭症，阅读障碍，躁狂症，抑郁症，冷漠和​​与糖尿病相关的肌病的新方法。 本文所述的胆碱酯酶抑制剂化合物。 本发明还描述了延迟阿尔茨海默氏病发作，增强认知功能，治疗和预防睡眠呼吸暂停，减轻戒烟综合征以及通过施用治疗有效量的至少一种治疗亨廷顿病的功能障碍的新方法 的本文所述的胆碱酯酶抑制剂化合物。 用于本发明方法的优选胆碱酯酶抑制剂是盐酸多奈哌齐或ARICEPT。

公开(公告)号：US20090042940A1

公开(公告)日：2009-02-12

申请号：US12192856

申请日：2008-08-15

申请人： John Ieni ,  Raymond Pratt

发明人： John Ieni ,  Raymond Pratt

IPC分类号： A61K31/445

CPC分类号： A61K31/13 ,  A61K9/0043 ,  A61K9/7023 ,  A61K31/15 ,  A61K31/435 ,  A61K31/44 ,  A61K45/06 ,  A61K2300/00

摘要： The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic stress disorder, anxiety disorders, panic attacks, obsessive-compulsive disorder, amnesia, and other disorders by administering to a patient in need thereof at least one cholinesterase inhibitor. The invention also provides novel pharmaceutical compositions that can be administered to the eyes or to the nose of patients. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof. In other embodiments, the cholinesterase inhibitor can be one or more of phenserine, tolserine, phenethylnorcymserine, ganstigmine, epastigmine, tacrine, physostigmine, pyridostigmine, neostigmine, rivastigmine, galantamine, citicoline, velnacrine, huperzine, metrifonate, heptastigmine, edrophonium, TAK-147, T-82, and upreazine.

摘要翻译： 本发明提供了治疗和/或预防阿尔茨海默病，精神疾病，脑炎，脑膜炎，胎儿酒精综合征，卡沙科夫综合征，缺氧性脑损伤，心肺复苏损伤，糖尿病，干燥综合征，智力迟钝，发育迟缓，绝经，中风， 黄斑变性，与黄斑变性相关的神经元损失，睡眠障碍，严重的阿尔茨海默氏病，时差，创伤后应激障碍，焦虑障碍，恐慌发作，强迫症，遗忘症和其他障碍，通过给予有需要的患者 至少一种胆碱酯酶抑制剂。 本发明还提供可以施用于患者的眼睛或鼻子的新型药物组合物。 在一个实施方案中，胆碱酯酶抑制剂是多奈哌齐，其立体异构体和/或其药学上可接受的盐。 在其它实施方案中，胆碱酯酶抑制剂可以是苯丝氨酸，丝氨酸，苯乙基乳清丝氨酸，甘曲斯坦，加曲霉素，他克林，毒扁豆隆，吡斯的明，新斯的明，利凡斯的明，加兰他敏，胞磷胆碱，维仑那明，石杉碱，甲伐他汀，庚斯的明， ，T-82和去乙嗪。

公开(公告)号：US20070053976A1

公开(公告)日：2007-03-08

申请号：US11523803

申请日：2006-09-20

申请人： Kazuo Sakai ,  John Ieni ,  Raymond Pratt

发明人： Kazuo Sakai ,  John Ieni ,  Raymond Pratt

IPC分类号： A61K31/165 ,  A61K31/137 ,  A61K31/381 ,  A61K31/405 ,  A61K9/20

CPC分类号： A61K45/06 ,  A61K31/137 ,  A61K31/165 ,  A61K31/381 ,  A61K31/405 ,  A61K2300/00

摘要： A novel antidepressant composition of a cholinesterase inhibitor in combination with a selective serotonin reuptake inhibitor, milnacipran or duloxetine is disclosed, which has a significantly high therapeutic effect as compared with conventional antidepressants. The therapeutic method using a cholinesterase inhibitor in combination with a selective serotonin reuptake inhibitor, milnacipran or duloxetine is beneficial for the treatment of depression, in particular, refractory depression.

摘要翻译： 公开了一种胆碱酯酶抑制剂与选择性5-羟色胺再摄取抑制剂米那普仑或度洛西汀组合的新型抗抑郁药组合物，其与常规抗抑郁药相比具有显着高的治疗效果。 使用胆碱酯酶抑制剂与选择性5-羟色胺再摄取抑制剂，米那普仑或度洛西汀组合的治疗方法有利于治疗抑郁症，特别是难治性抑郁症。

公开(公告)号：US06689795B2

公开(公告)日：2004-02-10

申请号：US10232406

申请日：2002-09-03

申请人： Raymond Pratt

发明人： Raymond Pratt

IPC分类号： A61K31445

CPC分类号： A61K31/445

摘要： The invention describes novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or dementia associated with neurologic and/or psychiatric conditions, including epilepsy, brain tumors, brain lesions, multiple sclerosis, Down's syndrome, Rett's syndrome, progressive supranuclear palsy, frontal lobe syndrome, and schizophrenia and related psychiatric disorders; cognitive impairments caused by traumatic brain injury, post coronary artery by-pass graft surgery, electroconvulsive shock therapy, and chemotherapy, administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The invention also describes novel methods for treating and preventing delirium, Tourette's syndrome, myasthenia gravis, attention deficit hyperactivity disorder, autism, dyslexia, mania, depression, apathy, and myopathy associated with diabetes by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The invention also describes novel methods for delaying the onset of Alzheimer's disease, for enhancing cognitive functions, for treating and preventing sleep apnea, for alleviating tobacco withdrawal syndrome, and for treating the dysfunctions of Huntington's Disease by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. A preferred cholinesterase inhibitor for use in the methods of the invention is donepezil hydrochloride or ARICEPT®.

摘要翻译： 本发明描述了用于治疗和预防由血管疾病引起的痴呆的新方法; 与帕金森病有关的痴呆; 路易体痴呆症 艾滋病痴呆; 轻度认知障碍; 年龄相关记忆障碍; 与神经和/或精神病学条件相关的认知障碍和/或痴呆，包括癫痫，脑肿瘤，脑损伤，多发性硬化，唐氏综合征，雷特综合征，进行性核上性麻痹，额叶综合征和精神分裂症及相关精神疾病; 由创伤性脑损伤，冠状动脉旁路移植手术，电惊醒性休克治疗和化疗引起的认知障碍，施用治疗有效量的至少一种本文所述的胆碱酯酶抑制剂化合物。 本发明还描述了通过施用治疗有效量的至少一种以上的治疗和预防呃妄，杜蕾特综合征，重症肌无力，注意缺陷多动障碍，自闭症，阅读障碍，躁狂症，抑郁症，冷漠和​​与糖尿病相关的肌病的新方法。 本文所述的胆碱酯酶抑制剂化合物。 本发明还描述了延迟阿尔茨海默氏病发作，增强认知功能，治疗和预防睡眠呼吸暂停，减轻戒烟综合征以及通过施用治疗有效量的至少一种治疗亨廷顿病的功能障碍的新方法 的本文所述的胆碱酯酶抑制剂化合物。 用于本发明方法的优选胆碱酯酶抑制剂是盐酸多奈哌齐或ARICEPT。

公开(公告)号：US20080167343A1

公开(公告)日：2008-07-10

申请号：US12073643

申请日：2008-03-07

申请人： John Ieni ,  Raymond Pratt

发明人： John Ieni ,  Raymond Pratt

IPC分类号： A61K31/44 ,  A61K31/4015 ,  A61P25/28

CPC分类号： A61K31/13 ,  A61K9/0043 ,  A61K9/7023 ,  A61K31/15 ,  A61K31/435 ,  A61K31/44 ,  A61K45/06 ,  A61K2300/00

摘要： The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic stress disorder, anxiety disorders, panic attacks, obsessive-compulsive disorder, amnesia, and other disorders by administering to a patient in need thereof at least one cholinesterase inhibitor. The invention also provides novel pharmaceutical compositions that can be administered to the eyes or to the nose of patients. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof. In other embodiments, the cholinesterase inhibitor can be one or more of phenserine, tolserine, phenethylnorcymserine, ganstigmine, epastigmine, tacrine, physostigmine, pyridostigmine, neostigmine, rivastigmine, galantamine, citicoline, velnacrine, huperzine, metrifonate, heptastigmine, edrophonium, TAK-147, T-82, and upreazine.

摘要翻译： 本发明提供了治疗和/或预防阿尔茨海默病，精神疾病，脑炎，脑膜炎，胎儿酒精综合征，卡沙科夫综合征，缺氧性脑损伤，心肺复苏损伤，糖尿病，干燥综合征，智力迟钝，发育迟缓，绝经，中风， 黄斑变性，与黄斑变性相关的神经元损失，睡眠障碍，严重的阿尔茨海默氏病，时差，创伤后应激障碍，焦虑障碍，恐慌发作，强迫症，遗忘症和其他障碍，通过给予有需要的患者 至少一种胆碱酯酶抑制剂。 本发明还提供可以施用于患者的眼睛或鼻子的新型药物组合物。 在一个实施方案中，胆碱酯酶抑制剂是多奈哌齐，其立体异构体和/或其药学上可接受的盐。 在其它实施方案中，胆碱酯酶抑制剂可以是苯丝氨酸，丝氨酸，苯乙基乳清丝氨酸，甘曲斯坦，加曲霉素，他克林，毒扁豆隆，吡斯的明，新斯的明，利凡斯的明，加兰他敏，胞磷胆碱，维仑那明，石杉碱，甲伐他汀，庚斯的明， ，T-82和去乙嗪。

公开(公告)号：US20070104799A1

公开(公告)日：2007-05-10

申请号：US11272563

申请日：2005-11-09

申请人： Raymond Pratt ,  Isobel Webster ,  Stephen Damment

发明人： Raymond Pratt ,  Isobel Webster ,  Stephen Damment

IPC分类号： A61K33/24

CPC分类号： A61K33/24

摘要： A subject with symptoms of chronic kidney disease (CKD), who does not have end-stage renal disease (ESRD), can be treated by orally administering a pharmaceutical composition as an active ingredient a therapeutically effective amount of a non-toxic lanthanum compound. Administration of a lanthanum compound can prevent the progression of CKD, treat soft tissue calcification, and treat secondary hyperparathyroidism.

摘要翻译： 可以通过口服给药治疗有效量的无毒镧化合物作为活性成分的药物组合治疗不具有终末期肾病（ESRD）的慢性肾脏疾病（CKD）症状的受试者。 镧化合物的施用可以预防CKD的进展，治疗软组织钙化和治疗继发性甲状旁腺功能亢进。

公开(公告)号：US20070048390A1

公开(公告)日：2007-03-01

申请号：US11347509

申请日：2006-02-02

申请人： Nigel Atherton ,  Michael Gaitonde ,  Joseph Totten ,  Peter Davies ,  Raymond Pratt

发明人： Nigel Atherton ,  Michael Gaitonde ,  Joseph Totten ,  Peter Davies ,  Raymond Pratt

IPC分类号： A61K33/24 ,  A61K31/59

CPC分类号： A61K33/24 ,  Y10S424/06 ,  Y10S514/825 ,  Y10S514/836 ,  Y10S514/90

摘要： The invention provides a method for enhancing bone formation, inhibiting osteoclastic differentiation and/or activating osteoblastic differentiation whereby to manage, treat or achieve prophylaxis of bone disease which comprises administering to a human or animal subject suffering from, or susceptible to bone disease a therapeutically or prophylactically effective amount of a lanthanum compound and a bone enhancing agent, such as vitamin D.

摘要翻译： 本发明提供了一种增强骨形成，抑制破骨细胞分化和/或激活成骨细胞分化的方法，其用于管理，治疗或实现骨疾病的预防，其包括向患有或易于骨疾病的人或动物受试者施用治疗或 预防有效量的镧化合物和骨增强剂，如维生素D.

公开(公告)号：US20060183776A9

公开(公告)日：2006-08-17

申请号：US10623577

申请日：2003-07-22

申请人： Raymond Pratt

发明人： Raymond Pratt

IPC分类号： A61K31/445

CPC分类号： A61K31/445 ,  Y02A50/401

摘要： The invention describes novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or dementia associated with neurologic and/or psychiatric conditions, including epilepsy, brain tumors, brain lesions, multiple sclerosis, Down's syndrome, Rett's syndrome, progressive supranuclear palsy, frontal lobe syndrome, and schizophrenia and related psychiatric disorders; cognitive impairments caused by traumatic brain injury, post coronary artery by-pass graft surgery, electroconvulsive shock therapy, and chemotherapy, administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The invention also describes novel methods for treating and preventing delirium, Tourette's syndrome, myasthenia gravis, attention deficit hyperactivity disorder, autism, dyslexia, mania, depression, apathy, and myopathy associated with diabetes by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. The invention also describes novel methods for delaying the onset of Alzheimer's disease, for enhancing cognitive functions, for treating and preventing sleep apnea, for alleviating tobacco withdrawal syndrome, and for treating the dysfunctions of Huntington's Disease by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compounds described herein. A preferred cholinesterase inhibitor for use in the methods of the invention is donepezil hydrochloride or ARICEPT®. The invention also provides orally administrable liquid dosage formulations comprising cholinesterase inhibitor compounds, such as ARICEPT®.

摘要翻译： 本发明描述了用于治疗和预防由血管疾病引起的痴呆的新方法; 与帕金森病相关的痴呆; 路易体痴呆症 艾滋病痴呆; 轻度认知障碍; 年龄相关记忆障碍; 与神经和/或精神病学条件相关的认知障碍和/或痴呆，包括癫痫，脑肿瘤，脑损伤，多发性硬化，唐氏综合征，雷特综合征，进行性核上性麻痹，额叶综合征和精神分裂症及相关精神疾病; 由创伤性脑损伤，冠状动脉旁路移植手术，电惊醒性休克治疗和化疗引起的认知障碍，施用治疗有效量的至少一种本文所述的胆碱酯酶抑制剂化合物。 本发明还描述了通过施用治疗有效量的至少一种以上的治疗和预防呃妄，杜蕾特综合征，重症肌无力，注意缺陷多动障碍，自闭症，阅读障碍，躁狂症，抑郁症，冷漠和​​与糖尿病相关的肌病的新方法。 本文所述的胆碱酯酶抑制剂化合物。 本发明还描述了延迟阿尔茨海默氏病发作，增强认知功能，治疗和预防睡眠呼吸暂停，减轻戒烟综合征以及通过施用治疗有效量的至少一种治疗亨廷顿病的功能障碍的新方法 的本文所述的胆碱酯酶抑制剂化合物。 用于本发明方法的优选胆碱酯酶抑制剂是盐酸多奈哌齐或ARICEPT。 本发明还提供了包含胆碱酯酶抑制剂化合物如ARICEPT的可口服给药的液体剂型。

公开(公告)号：US20080312189A1

公开(公告)日：2008-12-18

申请号：US10591608

申请日：2005-03-04

申请人： Raymond Pratt

发明人： Raymond Pratt

IPC分类号： A61K31/675 ,  A61K31/445 ,  A61K31/473 ,  A61K31/407 ,  A61K31/439 ,  A61P9/00 ,  A61K31/44 ,  A61K31/27 ,  A61K31/55

CPC分类号： A61K31/445 ,  A61K31/122 ,  A61K31/381 ,  A61K45/06 ,  A61K2300/00

摘要： The invention provides methods for treating and/or preventing cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) in a patient in need thereof by administering a therapeutically effective amount of at least one cholinesterase inhibitor. The invention also provides methods for treating and/or preventing neurovascular diseases caused by one or more mutations of the human Notch3 gene by administering a therapeutically effective amount of at least one cholinesterase inhibitor. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof. The methods of the invention may further include administering a therapeutically effective amount of an HMG-CoA reductase inhibitor

摘要翻译： 本发明通过施用治疗有效量的至少一种胆碱酯酶抑制剂，提供了在有需要的患者中治疗和/或预防脑常染色体显性动脉病变与皮质下梗死和白质脑病（CADASIL）的方法。 本发明还提供了通过施用治疗有效量的至少一种胆碱酯酶抑制剂来治疗和/或预防由人Notch3基因的一个或多个突变引起的神经血管疾病的方法。 在一个实施方案中，胆碱酯酶抑制剂是多奈哌齐，其立体异构体和/或其药学上可接受的盐。 本发明的方法还可包括施用治疗有效量的HMG-CoA还原酶抑制剂

公开(公告)号：US20060018839A1

公开(公告)日：2006-01-26

申请号：US10988600

申请日：2004-11-16

申请人： John Ieni ,  Raymond Pratt

发明人： John Ieni ,  Raymond Pratt

IPC分类号： A61L9/04 ,  A61K9/70 ,  A61K31/13

CPC分类号： A61K31/13 ,  A61K9/0043 ,  A61K9/7023 ,  A61K31/15 ,  A61K31/435 ,  A61K31/44 ,  A61K45/06 ,  A61K2300/00

摘要： The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic stress disorder, anxiety disorders, panic attacks, obsessive-compulsive disorder, amnesia, and other disorders by administering to a patient in need thereof at least one cholinesterase inhibitor. The invention also provides novel pharmaceutical compositions that can be administered to the eyes or to the nose of patients. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof. In other embodiments, the cholinesterase inhibitor can be one or more of phenserine, tolserine, phenethylnorcymserine, ganstigmine, epastigmine, tacrine, physostigmine, pyridostigmine, neostigmine, rivastigmine, galantamine, citicoline, velnacrine, huperzine, metrifonate, heptastigmine, edrophonium, TAK-147, T-82, and upreazine.

摘要翻译： 本发明提供了治疗和/或预防阿尔茨海默病，精神疾病，脑炎，脑膜炎，胎儿酒精综合征，卡沙科夫综合征，缺氧性脑损伤，心肺复苏损伤，糖尿病，干燥综合征，智力迟钝，发育迟缓，绝经，中风， 黄斑变性，与黄斑变性相关的神经元损失，睡眠障碍，严重的阿尔茨海默氏病，时差，创伤后应激障碍，焦虑障碍，恐慌发作，强迫症，遗忘症和其他障碍，通过给予有需要的患者 至少一种胆碱酯酶抑制剂。 本发明还提供可以施用于患者的眼睛或鼻子的新型药物组合物。 在一个实施方案中，胆碱酯酶抑制剂是多奈哌齐，其立体异构体和/或其药学上可接受的盐。 在其它实施方案中，胆碱酯酶抑制剂可以是苯丝氨酸，丝氨酸，苯乙基乳清丝氨酸，甘曲斯坦，加曲霉素，他克林，毒扁豆隆，吡斯的明，新斯的明，利凡斯的明，加兰他敏，胞磷胆碱，维仑那明，石杉碱，甲伐他汀，庚斯的明， ，T-82和去乙嗪。